SCHEMBL29523710

SCHEMBL29523710

COC(=O)CNC(=O)c1ccc(O[C@@H](C)c2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 6/20 0.55
LTB4R2 Q9NPC1 6/20 0.55
FFAR1 O14842 1/20 0.51
ATM Q13315 1/20 0.50
SLC6A9 P48067 1/20 0.49
SLC6A5 Q9Y345 1/20 0.49
GPR139 Q6DWJ6 3/20 0.49
MAPK1 P28482 1/20 0.47
NR1H4 Q96RI1 1/20 0.47
KDM4E B2RXH2 1/20 0.47
GAA P10253 1/20 0.47
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 2/20 0.46
TP53 P04637 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29523427 1.00 LTB4R (0.55) LTB4RLTB4R2FFAR1ATMSLC6A9
SCHEMBL29035350 1.00 LTB4R (0.55) LTB4RLTB4R2FFAR1ATMSLC6A9
SCHEMBL25364674 0.89 ATM (0.63) LTB4RLTB4R2FFAR1ATMSLC6A9
SCHEMBL25362664 0.89 ATM (0.63) LTB4RLTB4R2FFAR1ATMSLC6A9
SCHEMBL25362660 0.89 ATM (0.63) LTB4RLTB4R2FFAR1ATMSLC6A9
SCHEMBL8947296 0.80 MMP1 (0.68) MAPK1KDM4EGAAALDH1A1LMNA
SCHEMBL3961994 0.80 GAA (0.59) GPR139MAPK1KDM4EGAAALDH1A1
SCHEMBL29035407 0.79 LTB4R (0.57) LTB4RLTB4R2FFAR1GAAALDH1A1
SCHEMBL29523345 0.79 LTB4R (0.57) LTB4RLTB4R2FFAR1GAAALDH1A1
SCHEMBL29523814 0.79 LTB4R (0.57) LTB4RLTB4R2FFAR1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 EP disclosed
CN-116437913-A Pharmaceutical compounds for treating complement-mediated disorders 艾其林医药公司 2023-07-14 CN disclosed
WO-2022066774-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2022-03-31 WO disclosed